|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DNAJC19 |
Gene summary for DNAJC19 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DNAJC19 | Gene ID | 131118 |
| Gene name | DnaJ heat shock protein family (Hsp40) member C19 | |
| Gene Alias | PAM18 | |
| Cytomap | 3q26.33 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q96DA6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 131118 | DNAJC19 | LZE2T | Human | Esophagus | ESCC | 2.38e-07 | 1.39e+00 | 0.082 |
| 131118 | DNAJC19 | LZE4T | Human | Esophagus | ESCC | 1.17e-16 | 6.55e-01 | 0.0811 |
| 131118 | DNAJC19 | LZE5T | Human | Esophagus | ESCC | 3.74e-03 | 6.68e-01 | 0.0514 |
| 131118 | DNAJC19 | LZE7T | Human | Esophagus | ESCC | 1.07e-12 | 1.05e+00 | 0.0667 |
| 131118 | DNAJC19 | LZE8T | Human | Esophagus | ESCC | 1.43e-03 | 4.21e-01 | 0.067 |
| 131118 | DNAJC19 | LZE20T | Human | Esophagus | ESCC | 4.37e-07 | 6.08e-01 | 0.0662 |
| 131118 | DNAJC19 | LZE22T | Human | Esophagus | ESCC | 4.54e-08 | 8.53e-01 | 0.068 |
| 131118 | DNAJC19 | LZE24T | Human | Esophagus | ESCC | 8.00e-30 | 9.87e-01 | 0.0596 |
| 131118 | DNAJC19 | LZE21T | Human | Esophagus | ESCC | 2.41e-08 | 1.12e+00 | 0.0655 |
| 131118 | DNAJC19 | LZE6T | Human | Esophagus | ESCC | 4.64e-08 | 8.00e-01 | 0.0845 |
| 131118 | DNAJC19 | P1T-E | Human | Esophagus | ESCC | 1.80e-14 | 1.11e+00 | 0.0875 |
| 131118 | DNAJC19 | P2T-E | Human | Esophagus | ESCC | 5.37e-82 | 1.75e+00 | 0.1177 |
| 131118 | DNAJC19 | P4T-E | Human | Esophagus | ESCC | 1.65e-69 | 2.33e+00 | 0.1323 |
| 131118 | DNAJC19 | P5T-E | Human | Esophagus | ESCC | 1.30e-84 | 1.87e+00 | 0.1327 |
| 131118 | DNAJC19 | P8T-E | Human | Esophagus | ESCC | 9.56e-75 | 1.32e+00 | 0.0889 |
| 131118 | DNAJC19 | P9T-E | Human | Esophagus | ESCC | 8.41e-52 | 1.35e+00 | 0.1131 |
| 131118 | DNAJC19 | P10T-E | Human | Esophagus | ESCC | 8.05e-95 | 1.83e+00 | 0.116 |
| 131118 | DNAJC19 | P11T-E | Human | Esophagus | ESCC | 1.47e-24 | 1.53e+00 | 0.1426 |
| 131118 | DNAJC19 | P12T-E | Human | Esophagus | ESCC | 8.11e-105 | 2.42e+00 | 0.1122 |
| 131118 | DNAJC19 | P15T-E | Human | Esophagus | ESCC | 8.78e-66 | 1.81e+00 | 0.1149 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:007058512 | Liver | HCC | protein localization to mitochondrion | 101/7958 | 125/18723 | 1.53e-18 | 1.86e-16 | 101 |
| GO:000662612 | Liver | HCC | protein targeting to mitochondrion | 82/7958 | 100/18723 | 4.93e-16 | 4.05e-14 | 82 |
| GO:001703811 | Liver | HCC | protein import | 140/7958 | 206/18723 | 1.12e-13 | 6.46e-12 | 140 |
| GO:199054212 | Liver | HCC | mitochondrial transmembrane transport | 78/7958 | 102/18723 | 2.73e-12 | 1.26e-10 | 78 |
| GO:007180611 | Liver | HCC | protein transmembrane transport | 47/7958 | 59/18723 | 5.82e-09 | 1.51e-07 | 47 |
| GO:006500211 | Liver | HCC | intracellular protein transmembrane transport | 41/7958 | 51/18723 | 3.41e-08 | 7.61e-07 | 41 |
| GO:00066444 | Liver | HCC | phospholipid metabolic process | 214/7958 | 383/18723 | 7.25e-08 | 1.48e-06 | 214 |
| GO:004648611 | Liver | HCC | glycerolipid metabolic process | 215/7958 | 392/18723 | 4.54e-07 | 7.49e-06 | 215 |
| GO:00447431 | Liver | HCC | protein transmembrane import into intracellular organelle | 29/7958 | 36/18723 | 3.42e-06 | 4.49e-05 | 29 |
| GO:00192162 | Liver | HCC | regulation of lipid metabolic process | 181/7958 | 331/18723 | 4.58e-06 | 5.79e-05 | 181 |
| GO:00066504 | Liver | HCC | glycerophospholipid metabolic process | 168/7958 | 306/18723 | 7.27e-06 | 8.62e-05 | 168 |
| GO:00301501 | Liver | HCC | protein import into mitochondrial matrix | 17/7958 | 20/18723 | 1.18e-04 | 9.87e-04 | 17 |
| GO:006145811 | Liver | HCC | reproductive system development | 205/7958 | 427/18723 | 1.16e-02 | 4.27e-02 | 205 |
| GO:007259418 | Oral cavity | OSCC | establishment of protein localization to organelle | 284/7305 | 422/18723 | 1.50e-32 | 1.35e-29 | 284 |
| GO:000645718 | Oral cavity | OSCC | protein folding | 154/7305 | 212/18723 | 1.89e-23 | 4.60e-21 | 154 |
| GO:000660520 | Oral cavity | OSCC | protein targeting | 204/7305 | 314/18723 | 6.78e-21 | 1.13e-18 | 204 |
| GO:000683918 | Oral cavity | OSCC | mitochondrial transport | 162/7305 | 254/18723 | 8.96e-16 | 6.52e-14 | 162 |
| GO:001703815 | Oral cavity | OSCC | protein import | 136/7305 | 206/18723 | 3.15e-15 | 2.08e-13 | 136 |
| GO:007058518 | Oral cavity | OSCC | protein localization to mitochondrion | 91/7305 | 125/18723 | 1.60e-14 | 9.27e-13 | 91 |
| GO:007265518 | Oral cavity | OSCC | establishment of protein localization to mitochondrion | 88/7305 | 120/18723 | 2.10e-14 | 1.19e-12 | 88 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DNAJC19 | SNV | Missense_Mutation | novel | c.70N>A | p.Gln24Lys | p.Q24K | Q96DA6 | protein_coding | tolerated(0.21) | benign(0.06) | TCGA-A2-A1FW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
| DNAJC19 | SNV | Missense_Mutation | rs199774384 | c.251N>A | p.Arg84Gln | p.R84Q | Q96DA6 | protein_coding | tolerated(0.1) | benign(0.012) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DNAJC19 | SNV | Missense_Mutation | novel | c.220N>T | p.Asn74Tyr | p.N74Y | Q96DA6 | protein_coding | deleterious(0.01) | possibly_damaging(0.831) | TCGA-C5-A7X5-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
| DNAJC19 | SNV | Missense_Mutation | c.119N>C | p.Leu40Pro | p.L40P | Q96DA6 | protein_coding | deleterious(0) | possibly_damaging(0.819) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DNAJC19 | SNV | Missense_Mutation | novel | c.301N>A | p.Ala101Thr | p.A101T | Q96DA6 | protein_coding | tolerated(0.53) | benign(0.072) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| DNAJC19 | SNV | Missense_Mutation | rs199774384 | c.251N>A | p.Arg84Gln | p.R84Q | Q96DA6 | protein_coding | tolerated(0.1) | benign(0.012) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
| DNAJC19 | deletion | Frame_Shift_Del | c.348delN | p.Lys116AsnfsTer6 | p.K116Nfs*6 | Q96DA6 | protein_coding | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
| DNAJC19 | SNV | Missense_Mutation | novel | c.198A>G | p.Ile66Met | p.I66M | Q96DA6 | protein_coding | deleterious(0) | possibly_damaging(0.715) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
| DNAJC19 | SNV | Missense_Mutation | rs750384728 | c.58C>T | p.Arg20Cys | p.R20C | Q96DA6 | protein_coding | deleterious(0.01) | benign(0) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| DNAJC19 | SNV | Missense_Mutation | rs199774384 | c.251G>A | p.Arg84Gln | p.R84Q | Q96DA6 | protein_coding | tolerated(0.1) | benign(0.012) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |